AUS
NZ
UK
CA
USA
IND
Highlights
- Tryptamine Therapeutics Ltd achieves safety milestone in psilocin IV infusion trial.
- TRP-8803 deemed safe after Phase 1b study involving 11 participants.
- Further trials planned, with preparations for a Phase 2 study underway.
Tryptamine Therapeutics Ltd (ASX:TYP) has reached an important milestone in its clinical development program, receiving a green light from its Safety Committee on the safety of its IV-infused psilocin treatment. The company’s product, TRP-8803, was deemed safe for use during a Phase 1b trial, marking a significant step forward in its exploration of psilocin to treat various psychological and health conditions, positioning it among innovative ASX healthcare stocks.
The trial involved administering psilocin, a compound derived from the hallucinogenic substance psilocybin, to 11 healthy participants via IV infusion. The trial lasted up to 150 minutes, and participants were given varying levels of the treatment to assess its safety and effects. This Phase 1b study focused specifically on healthy volunteers to establish a solid foundation for broader clinical use.
With this safety milestone behind them, Tryptamine Therapeutics is now turning its attention to a more comprehensive review of the trial data. The company’s next objective is to analyze the results in preparation for the larger Phase 2 trial, which will focus on more targeted patient groups.
This achievement follows previous success for Tryptamine Therapeutics in Phase 2a trials of an oral psilocybin treatment, TRP-8802. The oral treatment has shown promising outcomes for patients with conditions such as Binge Eating Disorder and Fibromyalgia, two areas that the company has been focusing on in its quest to develop innovative treatments for mental health and related conditions.
The company’s CEO, Jason Carroll, expressed confidence in the progress made with TRP-8803, noting that the safety clearance is a major step forward for Tryptamine’s drug development efforts. He explained that the data gathered from the Phase 1b study will enable the company to better understand the potential benefits of TRP-8803, as well as optimize its pharmacokinetic profile to ensure precise blood levels during treatment.
The upcoming Phase 2 trial will be the next step in confirming the treatment’s potential, with plans to focus on specific indications that could benefit from this approach. Tryptamine Therapeutics Ltd continues to move forward in its mission to develop innovative solutions for patients dealing with challenging health conditions.
